Libya vs Saint Vincent and the Grenadines: Hepatitis B surface antigen (HBsAg) prevalence
Libya
0.2%
in 2024
Saint Vincent and the Grenadines
0.2%
in 2024
Libya rank
82nd
Saint Vincent and the Grenadines rank
82nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Libya
- Saint Vincent and the Grenadines
How they compare
Libya currently reports 0.2% against 0.2% in Saint Vincent and the Grenadines, a difference of 0.0%.
Across all 10 years both countries report, Saint Vincent and the Grenadines has been ahead every year.
Libya ranks 82nd and Saint Vincent and the Grenadines ranks 82nd of 194 countries.
Saint Vincent and the Grenadines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Libya | Saint Vincent and the Grenadines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Saint Vincent and the Grenadines |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Libya or Saint Vincent and the Grenadines?
- Libya, at 0.2% against 0.2% in Saint Vincent and the Grenadines as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Libya and Saint Vincent and the Grenadines?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and Saint Vincent and the Grenadines?
- 10 years are reported by both, from 2015 to 2024.
- How do Libya and Saint Vincent and the Grenadines rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Libya ranks 82nd and Saint Vincent and the Grenadines ranks 82nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.